Patents by Inventor Takashi Sonobe
Takashi Sonobe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8583192Abstract: A base station device for making communications with a mobile terminal includes a communication monitoring unit that monitors a communication situation between the base station device and the mobile terminal; and an operational-power control unit that causes, when the communication monitoring unit detects that no communications between the base station device and the mobile terminal have been made for a predetermined continuous period or longer, the base station device to operate at a power lower than a predetermined power.Type: GrantFiled: January 14, 2011Date of Patent: November 12, 2013Assignee: Fujitsu LimitedInventors: Tetsuo Tomita, Takashi Sonobe
-
Patent number: 8532018Abstract: A mobile communication system includes a data multiplexer which divides by time a radio frame of a communication channel in a radio layer and multiplexes one of a plurality of pieces of multicast data and a plurality of pieces of broadcast data into the divided radio frames; and a data multiplex demultiplexer which demultiplexes, when receiving one of the plurality of pieces of multicast data and the plurality of pieces of broadcast data multiplexed by the data multiplexer, the multiplexing of the received data.Type: GrantFiled: October 27, 2010Date of Patent: September 10, 2013Assignee: Fujitsu LimitedInventors: Tetsuo Tomita, Takashi Sonobe
-
Publication number: 20110105200Abstract: A base station device for making communications with a mobile terminal includes a communication monitoring unit that monitors a communication situation between the base station device and the mobile terminal; and an operational-power control unit that causes, when the communication monitoring unit detects that no communications between the base station device and the mobile terminal have been made for a predetermined continuous period or longer, the base station device to operate at a power lower than a predetermined power.Type: ApplicationFiled: January 14, 2011Publication date: May 5, 2011Applicant: FUJITSU LIMITEDInventors: Tetsuo TOMITA, Takashi SONOBE
-
Publication number: 20110098041Abstract: A radio controller performs call connection when a connection request is sent from a UE that exists in a macrocell accommodated by a macrocell base station. Thereafter, when the radio controller receives the connection request from the UE that exists in the macrocell accommodated by the macrocell base station, the radio controller searches for a femtocell that is adjacent to or overlaps the macrocell in which the UE exists and a femto base station that accommodates the femtocell. The radio controller instructs the searched femto base station to resume. The radio controller then instructs the UE to be handed over to the femtocell.Type: ApplicationFiled: December 30, 2010Publication date: April 28, 2011Applicant: FUJITSU LIMITEDInventors: Tetsuo TOMITA, Takashi SONOBE
-
Publication number: 20110038298Abstract: A mobile communication system includes a data multiplexer which divides by time a radio frame of a communication channel in a radio layer and multiplexes one of a plurality of pieces of multicast data and a plurality of pieces of broadcast data into the divided radio frames; and a data multiplex demultiplexer which demultiplexes, when receiving one of the plurality of pieces of multicast data and the plurality of pieces of broadcast data multiplexed by the data multiplexer, the multiplexing of the received data.Type: ApplicationFiled: October 27, 2010Publication date: February 17, 2011Applicant: FUJITSU LIMITEDInventors: Tetsuo TOMITA, Takashi SONOBE
-
Publication number: 20070286898Abstract: [Problem] To provide a drug delivery system which is retained in the blood circulation and improves pharmacological effect of the drug in the target organ and cell. [Means for Resolution] A drug-containing liposome for use in the treatment with a liposome prepared by employing polyethylene glycol cholesteryl ether as a part of the liposome-forming agent and using said liposome-forming agent. It is possible to obtain excellent drug effect by further employing a polyethylene glycol diacylglycerol ester as a part of the liposome-forming agent.Type: ApplicationFiled: August 30, 2005Publication date: December 13, 2007Applicants: ASTELLAS PHARMA INC., TAKASHI SONOBEInventors: Akira Takagi, Noboru Yamashita, Takashi Sonobe, Yasuyuki Sadzuka
-
Patent number: 4879119Abstract: A patch having good transdermal property which utilizes a suppository base e.g. triglyceride of a vegetable saturated fatty acid having 12 to 18 carbon atoms together with a penetration enhancer.Type: GrantFiled: August 26, 1988Date of Patent: November 7, 1989Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yutaka Konno, Hiroitsu Kawata, Masayoshi Aruga, Takashi Sonobe, Mitsuo Mitomi
-
Patent number: 4842577Abstract: A novel plaster structural assembly is provided for iontophoresis wherein th e assembly is comprised of an electrode layer and a medicament-containing layer in which a water supplying layer is disposed between the electrode layer and the medicament-containing layer with a sealing cover disposed on the outside of the electrode layer. A method for using the structural assembly for iontophoresis is also provided.Type: GrantFiled: October 16, 1987Date of Patent: June 27, 1989Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yutaka Konno, Mitsuo Mitomi, Takashi Sonobe, Shumpei Yamaguchi
-
Patent number: 4788221Abstract: Pharmaceutical compositions for intranasal administration comprising (a) calcitonin and (b) at least one absorption enhancer selected from the group consisting of benzyl alcohol, ethanol, thiamine or a salt thereof, salicylic acid or a salt thereof, capric acid or a salt thereof, Macrogol 400, pyridoxal or a salt thereof, malic acid or a salt thereof and pyrophosphoric acid or a salt thereof, in (c) a liquid diluent or carrier, suitable for application to the nasal mucosa.Type: GrantFiled: May 5, 1987Date of Patent: November 29, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Seiya Kagatani, Shunji Hasumi, Takashi Sonobe, Masayoshi Aruga
-
Patent number: 4765988Abstract: Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.Type: GrantFiled: May 5, 1987Date of Patent: August 23, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Takashi Sonobe, Hiroshi Sugiura, Tomoh Itoh, Masayoshi Aruga, Hiroitsu Kawata
-
Patent number: 4758437Abstract: A spherical pellet like composition of nicardipine composed of small granular nuclei such as sugar particles coated with amorphous nicardipine or a salt thereof, a pH-dependent additive and a surface active agent. The spherical pellet like composition of nicardipine may have a further coating of a medicament permeating material as an outermost coating. The spherical pellet like composition may be mixed with the spherical pellet like composition coated with the medicament permeating material.Type: GrantFiled: February 11, 1987Date of Patent: July 19, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Takashi Sonobe, Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Satoru Yoneya, Chiharu Yamada, Yukio Kubota
-
Patent number: 4724148Abstract: Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.Type: GrantFiled: November 14, 1986Date of Patent: February 9, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Takashi Sonobe, Hiroshi Sugiura, Tomoh Itoh, Masayoshi Aruga, Hiroitsu Kawata
-
Patent number: 4690952Abstract: Pharmaceutical compositions for intranasal administration comprising (a) calcitonin and (b) at least one absorption enhancer selected from the group consisting of benzyl alcohol, ethanol, thiamine or a salt thereof, salicylic acid or a salt thereof, capric acid or a salt thereof, Macrogol 400, pyridoxal or a salt thereof, malic acid or a salt thereof and pyrophosphoric acid or a salt thereof, in (c) a liquid diluent or carrier, suitable for application to the nasal mucosa.Type: GrantFiled: November 22, 1985Date of Patent: September 1, 1987Assignee: Yamanouchi Pharmaceutical Co., Inc.Inventors: Seiya Kagatani, Shunji Hasumi, Takashi Sonobe, Masayoshi Aruga
-
Patent number: 4685911Abstract: A patch having good transdermal property which utilizes a suppository base e.g. triglyceride of a vegetable saturated fatty acid having 12 to 18 carbon atoms together with a penetration enhancer.Type: GrantFiled: February 8, 1985Date of Patent: August 11, 1987Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yutaka Konno, Hiroitsu Kawata, Masayoshi Aruga, Takashi Sonobe, Mitsuo Mitomi
-
Patent number: 4673564Abstract: Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material in nicardipine, the composition may consist only of the amorphous nicardipine oType: GrantFiled: October 23, 1985Date of Patent: June 16, 1987Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Takashi Sonobe, Satoru Yoneya, Chiharu Sone
-
Patent number: 4637930Abstract: A formulation is provided for the transdermal administration of nicardipine hydrochloride. The formulation is comprised of nicardipine hydrochloride dissolved or suspended in a mixed liquid composed of an urea and at least one compound selected from the group consisting of propylene glycol, a monohydric alcohol having 2 to 4 carbon atoms, lactic acid, thioglycol, a middle chain fatty acid glyceride and a sorbitan middle chain fatty acid ester compounded with a transdermal formulation base.Type: GrantFiled: January 31, 1985Date of Patent: January 20, 1987Assignee: Yamanouchi Pharmaceutical Co, Ltd.Inventors: Yutaka Konno, Hiroitsu Kawata, Masayoshi Aruga, Takashi Sonobe, Mitsuo Mitomi
-
Patent number: 4404183Abstract: Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine oType: GrantFiled: July 29, 1982Date of Patent: September 13, 1983Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Takashi Sonobe, Satoru Yoneya, Chiharu Sone
-
Patent number: 4343789Abstract: Sustained release pharmaceutical composition of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment): and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine orType: GrantFiled: July 2, 1980Date of Patent: August 10, 1982Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Takashi Sonobe, Satoru Yoneya, Chiharu Sone